» Articles » PMID: 36359246

Molecular and Cellular Markers in Chlorhexidine-Induced Peritoneal Fibrosis in Mice

Overview
Journal Biomedicines
Date 2022 Nov 11
PMID 36359246
Authors
Affiliations
Soon will be listed here.
Abstract

Understanding the tissue changes and molecular mechanisms of preclinical models is essential for creating an optimal experimental design for credible translation into clinics. In our study, a chlorhexidine (CHX)-induced mouse model of peritoneal fibrosis was used to analyze histological and molecular/cellular alterations induced by 1 and 3 weeks of intraperitoneal CHX application. CHX treatment for 1 week already caused injury, degradation, and loss of mesothelial cells, resulting in local inflammation, with the most severe structural changes occurring in the peritoneum around the ventral parts of the abdominal wall. The local inflammatory response in the abdominal wall showed no prominent differences between 1 and 3 weeks. We observed an increase in polymorphonuclear cells in the blood but no evidence of systemic inflammation as measured by serum levels of serum amyloid A and interleukin-6. CHX-induced fibrosis in the abdominal wall was more pronounced after 3 weeks, but the gene expression of fibrotic markers did not change over time. Complement system molecules were strongly expressed in the abdominal wall of CHX-treated mice. To conclude, both histological and molecular changes were already present in week 1, allowing examination at the onset of fibrosis. This is crucial information for refining further experiments and limiting the amount of unnecessary animal suffering.

Citing Articles

Pulmonary Toxicity Assessment after a Single Intratracheal Inhalation of Chlorhexidine Aerosol in Mice.

Zhang J, Jiang X, Li X, Sun H, Wang M, Zhang W Toxics. 2023; 11(11).

PMID: 37999562 PMC: 10675078. DOI: 10.3390/toxics11110910.


Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review.

Fioretto B, Rosa I, Matucci-Cerinic M, Romano E, Manetti M Int J Mol Sci. 2023; 24(4).

PMID: 36835506 PMC: 9965592. DOI: 10.3390/ijms24044097.

References
1.
Stergar J, Hren R, Milanic M . Design and Validation of a Custom-Made Laboratory Hyperspectral Imaging System for Biomedical Applications Using a Broadband LED Light Source. Sensors (Basel). 2022; 22(16). PMC: 9416268. DOI: 10.3390/s22166274. View

2.
Borceux P, Morelle J, Goffin E . Complement system activation and peritoneal membrane alterations: Culprit or innocent bystander?. Perit Dial Int. 2020; 40(2):115-123. DOI: 10.1177/0896860819896242. View

3.
Ertilav M, Hur E, Bozkurt D, Sipahi S, Timur O, Sarsik B . Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model. Nephrology (Carlton). 2011; 16(6):552-7. DOI: 10.1111/j.1440-1797.2011.01460.x. View

4.
Lubbers R, van Essen M, van Kooten C, Trouw L . Production of complement components by cells of the immune system. Clin Exp Immunol. 2017; 188(2):183-194. PMC: 5383442. DOI: 10.1111/cei.12952. View

5.
Tanabe K, Maeshima Y, Ichinose K, Kitayama H, Takazawa Y, Hirokoshi K . Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int. 2006; 71(3):227-38. DOI: 10.1038/sj.ki.5002040. View